Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.

Leach K, Loiacono RE, Felder CC, McKinzie DL, Mogg A, Shaw DB, Sexton PM, Christopoulos A.

Neuropsychopharmacology. 2010 Mar;35(4):855-69. doi: 10.1038/npp.2009.194. Epub 2009 Nov 25.

2.

Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, Bymaster FP, Felder CC.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10978-83. doi: 10.1073/pnas.0800567105. Epub 2008 Aug 4.

3.
4.

The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis.

ROWNTREE DW, NEVIN S, WILSON A.

J Neurol Neurosurg Psychiatry. 1950 Feb;13(1):47-62. No abstract available.

5.

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia.

Roth BL, Sheffler DJ, Kroeze WK.

Nat Rev Drug Discov. 2004 Apr;3(4):353-9. Review. No abstract available.

PMID:
15060530
6.

Allosteric binding sites on cell-surface receptors: novel targets for drug discovery.

Christopoulos A.

Nat Rev Drug Discov. 2002 Mar;1(3):198-210. Review.

PMID:
12120504
7.

Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice.

Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15312-7.

8.

Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, Jeppesen L, Sheardown MJ, Sauerberg P, Fink-Jensen A.

Schizophr Res. 2000 May 5;42(3):249-59.

PMID:
10785583
9.

Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.

Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, Shannon H, Xia B, Deng C, Wess J.

Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10483-8.

10.

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM.

Arch Neurol. 1997 Apr;54(4):465-73.

PMID:
9109749
11.

Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects.

Snyder S, Greenberg D, Yamamura HI.

Arch Gen Psychiatry. 1974 Jul;31(1):58-61. Review. No abstract available.

PMID:
4152054

Supplemental Content

Support Center